No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.
about
Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patientsERCC1 Cys8092Ala and XRCC1 Arg399Gln polymorphisms predict progression-free survival after curative radiotherapy for nasopharyngeal carcinomaNucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy: A meta-analysis based on 44 studies.Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy.Predictive value of XPD polymorphisms on platinum-based chemotherapy in non-small cell lung cancer: a systematic review and meta-analysis.Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies.How close are we to customizing chemotherapy in early non-small cell lung cancer?Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han populationERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatinDNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy.The genetic variations in DNA repair genes ERCC2 and XRCC1 were associated with the overall survival of advanced non-small-cell lung cancer patients.MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2.Pharmacogenetics of chemotherapy efficacy in breast cancer.Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.Immune checkpoint inhibitors in lung cancer: an update.Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine.Methodological quality evaluation of systematic reviews or meta-analyses on ERCC1 in non-small cell lung cancer: a systematic review.A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy.Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma.Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer.Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer.
P2860
Q28382908-1ED20C2D-CC0B-48D3-B819-E984487408F7Q28390293-90D9C43D-3715-4FCE-BC45-73099F540D5BQ33733507-6E00C02D-BB03-4CE6-9984-AA0BF1157B56Q34742602-414F939B-28EC-4B79-B73A-27223B13E2E9Q34973738-521C11EF-CEEA-47F4-98EC-88D979ADAB9AQ35048754-86C94BF6-B996-442F-BF53-0C52B2FB5FF6Q35146944-1F864E24-4B25-4FAD-B941-821AB5447686Q35200402-8FE637AC-7694-49AE-A450-9B9F01490F25Q36681506-E81FBA07-F67E-4429-BCB1-7BE2D30C0EC5Q36893674-43E7CBD7-5148-44F1-8414-46E1DA7CD0A9Q36910455-291BB44E-9A45-493B-8D47-BDD2A0A331E0Q37321149-EE3A0693-2EB6-41F5-A0B2-07A50DB247CEQ37619736-A0409349-196F-4160-B2E6-BFB414C481B4Q38003703-0FD89741-347E-4734-BBBB-3CDC557C21D6Q38030053-3F1142C3-066E-4D89-AD2C-C933E9565890Q38171397-5CD037A5-FBB7-4104-B6BE-9F7A9AB44958Q38686642-FC30F586-423C-4ACD-B1A6-DB39D3FEE34EQ38909984-95D9D492-5BF5-44E7-A6D1-15EA6FE02A71Q40056604-54A1C790-508A-4539-8EBC-20AF9D7B8162Q40705223-1079FE6F-69B9-4C0B-9158-8BF8715BD856Q41758054-B931CBAD-7245-48A1-9E19-106A9597978EQ47309064-53A86431-9244-48B3-9872-A717FCE94515Q53627469-A03D8E95-60EE-4A6C-9D5E-F0893D092685Q54177115-43EA59EA-3176-4C41-B5BA-5C6A561022A1Q54478536-97DC1EC3-6310-4AD4-988D-BB87B9E24CE4
P2860
No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
No evidence of an association ...... lung cancer: a meta-analysis.
@ast
No evidence of an association ...... lung cancer: a meta-analysis.
@en
No evidence of an association ...... lung cancer: a meta-analysis.
@nl
type
label
No evidence of an association ...... lung cancer: a meta-analysis.
@ast
No evidence of an association ...... lung cancer: a meta-analysis.
@en
No evidence of an association ...... lung cancer: a meta-analysis.
@nl
prefLabel
No evidence of an association ...... lung cancer: a meta-analysis.
@ast
No evidence of an association ...... lung cancer: a meta-analysis.
@en
No evidence of an association ...... lung cancer: a meta-analysis.
@nl
P2093
P2860
P1433
P1476
No evidence of an association ...... lung cancer: a meta-analysis.
@en
P2093
Alexandra Voutsina
Carmelo Tibaldi
David C Christiani
Jingrong Yan
Qingyi Wei
Rebecca S Heist
Richard Booton
P2860
P304
P356
10.1016/J.LUNGCAN.2010.10.011
P577
2010-11-13T00:00:00Z